|
" Anthracycline Antibiotics in Cancer Therapy : "
edited by Franco M. Muggia, Charles W. Young, Stephen K. Carter.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
714093
|
| Doc. No
|
:
|
b536243
|
| Main Entry
|
:
|
edited by Franco M. Muggia, Charles W. Young, Stephen K. Carter.
|
| Title & Author
|
:
|
Anthracycline Antibiotics in Cancer Therapy : : Proceedings of the International Symposium on Anthracycline Antibiotics in Cancer Therapy, New York, New York, 16-18 September 1981\ edited by Franco M. Muggia, Charles W. Young, Stephen K. Carter.
|
| Publication Statement
|
:
|
Dordrecht: Springer Netherlands, 1982
|
| Series Statement
|
:
|
Developments in oncology, 10.
|
| Page. NO
|
:
|
(568 pages)
|
| ISBN
|
:
|
9400976305
|
|
|
:
|
: 9789400976306
|
| Contents
|
:
|
Section 1. Biolgical Effects --;Antitumor Activity of Anthracyclines: Experimental Studies --;Anthracycline Antitumor Antibiotics: Their Carcinogenicity and their Mutagenicity --;The Immunological Activity of Anthracyclines --;Section 2. Mechanism of Action --;Doxorubicin and Related Compounds. I. Physiochemical Characterization of the DNA Complex --;Consequences of DNA Intercalation: Protein-Associated DNA Strand Breaks --;Free Radical Damage --;Intracellular, Intranuclear, and Subchromosomal Localization of Anthracycline Antibiotics --;Effects of Anthracyclines on Macromolecules and their Syntheses --;Biotransformations of Anthracyclines in the Smooth Endoplasmic Reticulum of Rat Liver --;Transport and Storage of Anthracyclines in Experimental Systems and Human Leukemia --;Calcium Flux and Metabolism in the Pigeon Heart Following Doxorubicin Treatment: A Study of Acute Changes --;The Role of Acute Lipid Peroxidation in Doxorubicin Cardiotoxicity --;The Physicochemical Properties and Transmembraneous Transport of Doxorubicin --;Section 3. Drug Development --;Doxorubicin and Related Compounds. II. Structure-Activity Considerations --;Second-Generation Anthracyclines --;Factors in Selection of New Anthracyclines --;Implications of Free Radical Activation for Improved Anthracycline Therapy --;Screening for Second Generation Anthracyclines in a Human Tumor Cloning System --;Activity of Anthracyclines on Human Tumors in Vitro --;Pharmacologic and Therapeutic Characteristics of Anthracycline Liposome Preparation --;N-L-Leucyl Derivatives of Anthracyclines: Toxic and Chemotherapeutic Properties --;Alternative Methods of Drug Delivery --;Section 4. Cardiotoxicity --;The Role of Free Radical Damage in the Genesis of Doxorubicin Cardiac Toxicity --;Screening for Cardiotoxic Properties --;Role of Oxygen Radical Formation in Anthracycline Cardiac Toxicity --;Morphologic Assessment of Cardiac Lesions Caused by Anthracyclines --;Cardiac Monitoring of Patients Receiving Anthracyclines --;Reduction of Adriamycin Cardiac Toxicity by Schedule Manipulation --;Rationale and Design of a Trial to Evaluate the Cardiotoxicity of Weekly Schedules of Adriamycin, with Endomyocardial Biopsy Used as an End Point --;Anthracyclines in Cancer Chemotherapy --;Section 5. Doxorubicin: New Clinical Investigations --;Doxorubicin in the 1980s: Is there still Room for Clinical Investigation? --;A Phase I/II Study of 6-Hour and 24-Hour Intravenous Infusions of Doxorubicin --;Intravesical Chemotherapy in the Treatment and Prophylaxis of Bladder Tumors, with Special Reference to Doxorubicin --;Intraperitoneal Adriamycin in Ovarian Cancer --;Role of Adriamycin in Breast Cancer and Sarcomas --;Prospects for Doxorubicin in Adjuvant Breast Cancer Trials --;Clinical Evaluation of 4?-Epi Doxorubicin and 4-Demethoxy Daunorubicin --;Section 6. Clinical Studies with new Anthracyclines and Related Compounds --;The Anthracyclines --;A Historical Perspective --;Phase-I Trial with 4-Demethoxydaunorubicin --;Clinical Studies of New Anthracycline Analogs --;A Clinical Overview of Aclacinomycin A in Japan --;The Clinical Pharmacology of Aclacinomycin-A --;Phase II Evaluation of N-Trifluoroacetyladriamycin-14-Valerate (AD 32) --;Preliminary Experience with Marcellomycin: Preclinical and Clinical Aspects --;Preliminary Phase II Experience with 4?Epidoxorubicin.
|
| Abstract
|
:
|
Although the anthracycline antibiotics represent much of the present and future of cancer treatment, their actual use c stretches back barely two decades to the pioneering efforts of Aurelio Di Marco, who characterized the antitumor properties of daunomycin and adriamycin.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Oncology.
|
| Added Entry
|
:
|
C W Young
|
|
|
:
|
Franco M Muggia
|
|
|
:
|
Stephen K Carter
|
| |